Stroke Patients Benefit from Using AI

New York, NY - Results from a randomized controlled trial published this week in the American Heart Association’s journal Stroke demonstrate that stroke survivors were twice as likely to take anti-blood clot treatment (anticoagulants) when using an artificial intelligence (AI) platform than patients receiving treatment as usual.

The AI platform uses software algorithms on smartphones to automatically confirm patient identity, the medication, and medication ingestion. In addition, patients receive automated reminders and precise dosing instructions. Real-time data were available for review by health care workers. Early detection of nonadherence allowed for immediate follow up and ensured patients stayed on track in the intervention group.

“In the absence of routine laboratory monitoring, artificial intelligence has the potential to automate a critical component of care - adherence monitoring - and provide continuity of care between visits to ensure patients persist with their therapy and get full therapeutic benefit,” said Daniel Labovitz, MD, lead author and Director of the Stern Stroke Center at Montefiore Medical Center.

The 12-week study included ischemic stroke (clot caused) survivors randomly assigned to AI platform for daily monitoring or treatment as usual groups. To measure treatment adherence, researchers tested the concentration of medication in blood samples. Blood tests showed that 100% of patients in the intervention arm took medication regularly, compared to only half in the control arm. Participants were average age 57 years, 54 percent female, 46 percent black, 43 percent Hispanic, and 11 percent white.

In the United States, stroke is the fifth-leading cause of death and a major cause of long-term disability among survivors. Since the danger of having another stroke increases after a first stroke, preventive treatment is critical. In the past, healthcare providers needed to monitor anti-blood clot treatment for bleeding complications, but recently approved medications do not require monitoring. However, the reduced need for monitoring has placed pressure on patients to self-manage and leaves room for suboptimal adherence to go undetected; routine laboratory tests are not reliable indicators of adherence.

“Many patients are unable to self-manage and are at increased risk of stroke and bleeding,” said Laura Shafner, study coauthor and chief strategy officer at AiCure, New York City, the company that developed and tested the AI platform. “The use of technology and artificial intelligence has the potential to significantly improve health outcomes and reduce costs in clinical care.”

The study demonstrated that patients with little prior experience using a smartphone were able to easily learn how to use the technology and use it consistently. The AI platform is being deployed in drug development and population health settings, and demonstrating similar outcomes CNS and infectious disease. The AI platform is the only automated technology to be validated in ambulatory settings against drug concentration levels.

Study Highlights

• Blood tests showed that 100% of patients in the artificial intelligence intervention arm received full therapeutic benefit, compared to only 50% in the control arm.

• This was the first randomized controlled trial to compare adherence rates of all 3 DOACs (dabigatran, rivaroxaban, and apixaban) and warfarin together based on daily real-time monitoring against a control group, and verified by plasma sampling.

• Anti-blood clot treatment can prevent another stroke.

• 800,000 people suffer a stroke each year. Stroke is the fifth-leading cause of death.

Co-authors are Morayma Reyes Gil1, PhD; Deepti Virmani, MBBS; and Adam Hanina, MBA Author disclosures are on the manuscript.

Research reported in this release was supported by National Center for Advancing Translational Sciences of the National Institutes of Health under grant number R44 TR000873­02. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Additional Resources

• View the manuscript (https://doi.org/10.1161/STROKEAHA.116.016281 or http://stroke.ahajournals.org/content/early/2017/04/06/STROKEAHA.116.016281) online. The manuscript is assigned to the May issue of Stroke.

• Cumulative Effect - Stroke

Connect with AiCure:

• Follow us on Twitter: @AiCureMed

• Find us on LinkedIn

About AiCure
AiCure’s artificial intelligence visually confirms medication ingestion on any smartphone. The clinically-validated platform enables continuous monitoring and intervention for greater statistical power and sample size reductions in clinical trials and improved health outcomes in population health. AiCure has developed an extensive intellectual property portfolio and been funded by the National Institutes of Health and leading institutional investors. For more information, please visit www.aicure.com